Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A

Published:2020-01-01 Issue:1 Volume:12 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Zheng Songmao¹,Shen Fang²,Jones Brian²,Fink Damien¹,Geist Brian¹,Nnane Ivo³,Zhou Zhao²,Hall Jeff²,Malaviya Ravi²,Ort Tatiana²,Wang Weirong³

Affiliation:

1. Biologics Development Sciences, Janssen Biotherapeutics, Janssen R&D, Spring House, PA, USA

2. Immunology Discovery, Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

3. Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, PA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1770018

Reference51 articles.

1. Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases

2. Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases

3. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

4. Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

5. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-α and IL-17A, in autoimmune disease models;International Immunopharmacology;2024-07

2. Investigational bispecific antibodies for the treatment of rheumatoid arthritis;Expert Opinion on Investigational Drugs;2024-05-08

3. Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities;Expert Review of Clinical Pharmacology;2023-09-24

4. TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life;mAbs;2023-02-14

5. Utility of in silico prediction of target suppression for antibodies against soluble targets: static versus dynamic models;European Journal of Clinical Pharmacology;2022-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3